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Abstract
Background: Iron is essential for cell replication, metabolism and growth. Because neoplastic cells have high
iron requirements due to their rapid proliferation, iron depletion may be a novel therapeutic strategy for cancer.
Deferasirox (DFX), a novel oral iron chelator, has been successful in clinical trials in iron-overload patients and has
been expected to become an anticancer agent. However, no studies have investigated the effects of DFX on
pancreatic cancer. This study aimed to elucidate the effects of DFX against pancreatic cancer.
Methods: The effects of DFX on cell cycle, proliferation, and apoptosis were examined in three human pancreatic
cancer cell lines: BxPC-3, HPAF-II, and Panc 10.05. The effect of orally administered DFX on the growth of BxPC-3
pancreatic cancer xenografts was also examined in nude mice. Additionally, microarray analysis was performed
using tumors excised from xenografts.
Results: DFX inhibited pancreatic cancer cell proliferation in a dose-dependent manner. A concentration of 10 μM DFX
arrested the cell cycle in S phase, whereas 50 and 100 μM DFX induced apoptosis. In nude mice, orally administered
DFX at 160 and 200 mg/kg suppressed xenograft tumor growth with no serious side effects (n = 5; average tumor
volumes of 674 mm3 for controls vs. 327 mm3 for 160 mg/kg DFX, p <0.05; average tumor volumes of 674 mm3 for
controls vs. 274 mm3 for 200 mg/kg DFX, p <0.05). Importantly, serum biochemistry analysis indicated that serum levels
of ferritin were significantly decreased by the oral administration of 160 or 200 mg/kg DFX (n = 5; average serum
ferritin of 18 ng/ml for controls vs. 9 ng/ml for 160 mg/kg DFX, p <0.05; average serum ferritin of 18 ng/ml for
controls vs. 10 ng/ml for 200 mg/kg DFX, p <0.05). Gene expression analysis revealed that most genes in pancreatic
adenocarcinoma signaling, especially transforming growth factor-ß1 (TGF-ß1), were downregulated by DFX.
Conclusions: DFX has potential as a therapeutic agent for pancreatic cancer. Iron depletion was essential for the
antiproliferative effect of DFX in a preclinical model, and DFX acted through the suppression of TGF-ß signaling.
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Background
Pancreatic cancer is the fifth leading cause of cancer-
related deaths, and the number of cases has been in-
creasing in Japan [1]. It is the fifth and fourth leading
cause of cancer-related deaths in Europe and in North
America, respectively [2]. Pancreatic cancer is associated
with the worst prognosis among solid tumors [3]; the
5-year survival rate of pancreatic cancer, including resect-
able cases, is not more than 10 % [4]. Surgical resection is
the only potential curative therapy, but many patients with
pancreatic cancer are not candidates for surgical resection
at the time of diagnosis. For patients with unresectable
pancreatic cancer, chemotherapy is recommended as the
current standard care [5]. During the last two decades,
gemcitabine has been the standard chemotherapy for
pancreatic cancer. Recently, new combination chemo-
therapies have been developed, such as regimens combin-
ing fluorouracil, irinotecan, oxaliplatin, and leucovorin
(FOLFIRINOX) or albumin-bound paclitaxel with gemci-
tabine [6, 7]. However, while combination chemotherapies
have shown therapeutic advantages over single-agent gem-
citabine, they also have a high incidence of side effects. In
addition, more than half of pancreatic cancer patients are
diagnosed at an age of 65 years or older [4]. Therefore, a
new chemotherapeutic strategy for pancreatic cancer is re-
quired for these patients with refractory chemotherapy
due to side effects and/or advanced age.
Iron is essential for cell replication, metabolism and
growth [8]. Because neoplastic cells have high iron re-
quirements due to their rapid proliferation, iron depletion
could be a novel therapeutic strategy for cancer [9]. Al-
though iron chelators, which are commonly used for treat-
ing iron-overload disease, are not classified as anticancer
drugs; they exert antiproliferative effects in several cancers
[10–12]. We have reported that deferoxamine (DFO), a
standard iron chelator, can prevent the development of
liver preneoplastic lesions in rats [13]. We also performed
a pilot study using DFO in advanced hepatocellular car-
cinoma patients and reported the efficacy of this iron che-
lator [14]. Considering the mechanism of action of iron
chelators as anticancer agents, as well as other cancers,
iron chelators are thought to be effective pancreatic can-
cer treatments. Kovacevic et al. reported that thiosemicar-
bazone iron chelators inhibited pancreatic cancer growth
in vitro and in vivo [15]. Therefore, iron chelators repre-
sent a potential therapeutic strategy for pancreatic cancer.
However, most iron chelators, including DFO and thiose-
micarbazones, cannot be administered orally, thus limiting
their clinical application.
Recently, deferasirox (DFX), a newly developed oral
iron chelator, was successful in clinical trials in iron-
overload disease patients and has been implemented as
an alternative to DFO [16]. A number of in vitro and
in vivo studies have demonstrated that DFX has
powerful antiproliferative effects [17]. To our knowledge,
there have been no studies investigating the effects of
DFX against pancreatic cancer. Therefore, this study
aimed to evaluate the antiproliferative activity of DFX
against pancreatic cancer in vitro and in vivo.
Methods
Cell culture
The pancreatic cancer cell lines BxPC-3, HPAF-II, and
Panc 10.05 were obtained from the American Type
Culture Collection (Manassas, VA, USA). BxPC-3 and
Panc 10.05 cells are epithelial cell lines that were derived
from pancreatic adenocarcinomas. The HPAF-II cell line
consists of epithelial cells derived from ascites that origi-
nated from pancreatic adenocarcinomas.
BxPC-3 cells were grown in RPMI-1640 (Life
Technologies, Carlsbad, CA, USA) with 10 % (v/v)
fetal calf serum. HPAF-II cells were grown in Eagle’s
medium (Life Technologies) with 10 % (v/v) fetal calf
serum. Panc 10.05 cells were grown in RPMI-1640 (Life
Technologies) containing 10 units/ml of human recom-
binant insulin, and 15 % (v/v) fetal calf serum. All media
were supplemented with 50 μg/ml gentamicin. All cells
were incubated at 37 °C in a humidified atmosphere con-
taining 5 % CO2.
Reagents
The oral iron chelator DFX was obtained from Novartis
(Basel, Switzerland). For in vitro studies, DFX was dis-
solved in dimethyl sulfoxide at a stock concentration of
100 mM and was used at the concentrations indicated in
the results and figures by dilution in culture media con-
taining 10 % fetal calf serum. For in vivo studies, DFX
was dissolved in sodium chloride solution (0.9 % w/v;
Chemix Inc., Shinyokohama Kohoku-ku, Yokohama,
Japan).
Cell proliferation
Cellular proliferation was examined using the 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt (MTS) assay. Cell
suspensions (2,000 cells/100 μl) were added to each well
in a 96-multiwell culture plate (BD Bioscience, San Jose,
CA, USA) and incubated at 37 °C for 24 h. The indicated
concentrations of DFX were then added to each well, and
the cells were incubated for a further 72 h. At the end of
the culture period, 10 μl of MTS solution (Promega,
Madison, WI, USA) was added to each 100 μl of culture
media and incubated for 2 h. Absorbance at 490 nm was
measured with a multimode reader (Infinite 200 PRO,
Tecan Trading, AG, Switzerland), and the results are
expressed as the percentage viable with respect to the
untreated control.
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Cell cycle analysis
Each pancreatic cancer cell line was seeded into 100-mm
dishes and cultured with phosphate-buffered saline (PBS)
as a vehicle control or DFX at 10, 50, or 100 μM for 72 h.
After incubation, the cells were fixed with 70 % ethanol
and stored overnight at −20 °C. The cells were washed
and then stained with a solution containing 0.1 % Triton®
X-100 (Promega), 0.02 mg/ml propidium iodide (PI;
Sigma-Aldrich, St. Louis, MO, USA), and 0.2 mg/ml
RNase A (Qiagen, Hilden, Germany) in the dark at 37 °C
for 15 min. After staining, the cells were subjected to
cellular DNA content examination by a flow cytometer
(Gallios, Beckman Coulter, Fullerton, CA, USA). The data
were analyzed by Multicycle for Windows software
(Beckman Coulter).
Apoptosis analysis by flow cytometry
For the apoptosis analysis, the cells were cultured as de-
scribed above. After harvesting, apoptosis was evaluated
with an apoptosis detection kit (Annexin V Apoptosis
Detection Kit APC, eBioscience, San Diego, CA, USA)
according to the manufacturer’s instructions. After stain-
ing, the cells were examined using a flow cytometer
(Gallios, Beckman Coulter). The data were analyzed by
FlowJo software (Tree star, Ashland, OR, USA).
Apoptosis analysis with the luminescence assay
Cell suspensions (2,000 cells/100 μl) were added to each
well of a 96-multiwell culture plate (BD Bioscience) and
were incubated at 37 °C for 24 h. PBS as a vehicle
control or the indicated concentrations of DFX were
then added to each well, and the cells were further incu-
bated for 48 h. Immediately after the incubation, caspase
activity was measured using the caspase 3/7 assay kit
(Caspase-Glo 3/7 kit, Promega) according to the manu-
facturer’s instructions.
Tumor xenografts in nude mice and deferasirox
administration
Animal care was performed in accordance with the
animal ethics requirements at Yamaguchi University
School of Medicine, and the experimental protocol was
approved (approval ID 21-035). Twenty female BALB/c
(nu/nu) mice were purchased from Nippon SLC
(Shizuoka, Japan) and were housed in sterile conditions.
Experiments commenced when the mice were 8–10
weeks of age. Tumor cells (BxPC-3) in culture were har-
vested and resuspended in a 1:1 ratio of RPMI-1640 and
Matrigel (BD Bioscience). Viable cells (5 × 106 cells) were
injected subcutaneously into the backs of the mice. After
engraftment, tumor size was measured using Vernier
calipers every 2 days, and tumor volume was calculated
as follows: tumor volume (mm3) = (the longest diameter)
(mm) × (the shortest diameter) (mm)/2. When tumor
volumes reached 150 mm3, oral treatment began (day 0).
Each group of mice (n = 5) received DFX suspended in
saline, which was administered by oral gavage every sec-
ond day, with three treatments per week, over 21 days at
concentrations of 120, 160, or 200 mg/kg. The control
mice were treated with the vehicle alone. At the end of
the experiment, the mice were sacrificed, and the tumors
were excised and processed for immunohistochemistry
and genetic analyses. A total of 20 blood samples were
collected simultaneously during tumor removal. Serum
levels of ferritin were measured using the enzyme-linked
immunoassay method (Mouse Ferritin ELISA kit,
Kamiya Biochemical Company, Seattle, WA, USA).
Serum biochemistry with the exception of ferritin was
analyzed by YAMAGUCHI Laboratory Co., Ltd. (Ube,
Japan).
Immunohistochemistry
The removed tumors were fixed in 4 % paraformal-
dehyde (Muto-kagaku, Tokyo, Japan), sectioned, and
embedded in paraffin. Immunohistochemistry was per-
formed as previously described on the paraffin sections
with antibody specific to ferritin-H (Anti-Ferritin Heavy
Chain antibody, AbCam, Cambridge, MA, USA) [18].
The slides were scored according to the intensity of the
immunoreactivity and the percentage of epithelial cells
stained [19].
The detection of gene expression alternation in resected
tumors induced by deferasirox administration
Total RNA isolation
A total of six tumors were genetically analyzed. Of these,
three tumors were removed from vehicle-treated mice,
and the other three tumors were removed from DFX
200 mg/kg-treated mice. According to the manu-
facturer’s instructions, total RNA was isolated from the
removal tumors using TRIzol Reagent (Invitrogen Corp.,
CA, USA) and purified using the SV Total RNA
Isolation System (Promega). RNA samples were quanti-
fied using a NanoDrop ND-1000 spectrophotometer
(Thermo Fisher Scientific Inc., Wilmington, DE, USA),
and RNA quality was checked using an Experion auto-
mated electrophoresis station (Bio-Rad Laboratories Inc.,
Hercules, CA, USA).
Gene expression microarrays
The cRNA was amplified, labeled, and hybridized to a
60K Agilent 60-mer oligomicroarray according to the
manufacturer’s instructions. All hybridized microarray
slides were scanned by an Agilent scanner. Relative
hybridization intensities and background hybridization
values were calculated using Agilent Feature Extraction
Software (9.5.1.1).
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Data analysis and filter criteria
The raw signal intensities of all samples were log2-
transformed and normalized with a quantile algorithm
from the ‘preprocessCore’ library package [20] on
Bioconductor software [21]. We selected the probes, ex-
cluding the control probes, where the detection p-values
of all samples were less than 0.05, and used them to iden-
tify differentially expressed genes. To determine significant
enrichment canonical pathways, we used the tools and
data provide by the Ingenuity Pathway Analysis (IPA)
(Ingenuity Systems, INC. http://www.ingenuity.com). The
results are the comparisons of tumors removed from
vehicle-treated mice vs. the tumors removed from DFX
200 mg/kg-treated mice.
Statistical analyses
All obtained data are calculated and expressed as the
mean ± SD. In the in vitro experiments, the differences
were analyzed statistically using 1-way ANOVA, followed
by Dannett’s test. In the in vivo experiments, the differ-
ences were analyzed statistically using the Kruskal-Wallis
H test, followed by Steel’s test. JMP 9 statistical software
(SAS Institute Inc., Cary, NC, USA) was used in the
analysis. Values of p <0.05 were considered significant.
Results
DFX inhibited cell proliferation in pancreatic cancer cell
lines
To examine the antiproliferative activity of DFX against
pancreatic cancer in vitro, the pancreatic cancer cell
lines BxPC-3, HPAF-II, and Panc 10.05 were incubated
with either vehicle control (PBS) or the indicated con-
centrations of DFX for 72 h; then, the cell survival rates
were measured using the MTS assay. The cell survival
rates are shown in Fig. 1. Incubation of all three cell
lines with DFX inhibited cellular proliferation in a dose-
dependent manner. DFX had the same level of
antiproliferative activity in all three cell lines. As
indicated in Table 1, the IC50 values for the BxPC-3,
HPAF-II, and Panc 10.05 pancreatic cancer cell lines
were 7.3 ± 1.0, 5.6 ± 1.0, and 6.1 ± 0.2 μM, respectively.
There were no significant differences in the IC50 values
of each pancreatic cancer cell line.
DFX arrested the cell cycle at the S phase in pancreatic
cancer cell lines
To explore the mechanism of the antiproliferative
activity of DFX, the pancreatic cancer cell lines BxPC-3,
HPAF-II, and Panc 10.0 were incubated with either the
vehicle control (PBS) or 10, 50, or 100 μM concentra-
tions of DFX for 72 h, and the cell cycle was examined
with flow cytometry using PI staining. The analyzed re-
sults are shown in Fig. 2a, and the percentage of S phase
cells are highlighted in pink. The percentage of S phase
cells for each concentration of DFX is shown in Fig. 2b.
In all three cell lines, the percentage of S phase cells
incubated with 10 μM concentration of DFX was in-
creased. These results demonstrated that 10 μM DFX
arrested the cell cycle of pancreatic cancer cells in S phase.
DFX induced apoptosis in pancreatic cancer cell lines
To further characterize the mechanisms of the antipro-
liferative activity of DFX, the pancreatic cancer cell lines
BxPC-3, HPAF-II, and Panc 10.0 were incubated with
either the vehicle control (PBS) or concentrations of 10,
50, or 100 μM of DFX for 72 h, and apoptosis was exam-
ined by flow cytometry using PI and Annexin V staining.
The results are shown in Fig. 3a. The amount of live
cells was defined as the number of cells negative for
both Annexin V and PI. The amount of cells in early
apoptosis was defined as cells positive for Annexin V
only, whereas late apoptosis was defined as cells positive
for both Annexin V and PI. The amount of necrotic cells
was defined as the cells negative for Annexin V but
Fig. 1 DFX inhibited the proliferation of pancreatic cancer cell lines. Cell proliferation was measured using the MTS assay after cells were treated
with DFX 72 h. The viability of BxPC-3, HPAF-II, and Panc 10.05 cells incubated with DFX decreased in a dose-dependent manner. The data are
presented as the mean ± SD (n = 3–5). *p <0.05, **p <0.01 vs. control
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positive for PI. The percentages of live, apoptotic, and
necrotic cells are shown in Fig. 3b. Incubation with 50
or 100 μM DFX significantly decreased the number of
live cells compared with control cells in all three cell
lines. Moreover, incubation with 50 or 100 μM DFX typ-
ically increased the number of cells in late apoptosis in
all three cell lines. Apoptosis was also examined by
measuring the caspase 3/7 activity with a luminescence
assay. The analyzed results are shown in Fig. 4. In all
three cell lines, the caspase 3/7 activities were signifi-
cantly higher in cells incubated with 100 μM of DFX
compared with control cells. These results demonstrated
that 50 and 100 μM DFX induced apoptosis in pancre-
atic cancer cells.
DFX inhibited the growth of human pancreatic cancer
xenografts
Next, the antiproliferative activity of DFX against pan-
creatic cancer was assessed in vivo using BxPC-3 pan-
creatic cancer xenografts in BALB/c nude mice. As DFX
is given to patients orally, we administered DFX as a
saline suspension given orally in accordance with previ-
ous studies [22, 23]. DFX administered orally at 160 and
200 mg/kg (every second day, three treatments per week
for 21 days) resulted in marked inhibition of tumor
growth as determined by measurements of tumor volume
and tumor weight (Fig. 5a, b, and c). After 21 days of oral
treatment with the vehicle control (saline solution),
the tumor xenografts reached an average volume of
674 ± 150 mm3. In contrast, the tumor volumes were sig-
nificantly reduced to 327 ± 45 and 274 ± 67 mm3 in mice
treated with 160 and 200 mg/kg DFX, respectively (Fig. 5a).
At the end of the experiment, the tumors were excised and
measured. The control tumors weighed 0.6 ± 0.2 g, whereas
tumors treated with 160 and 200 mg/kg oral DFX weighed
significantly less than the control tumors at 0.4 ± 0.04 and
0.3 ± 0.1 g, respectively (Fig. 5c). Furthermore, in the
blood sample examinations, DFX administered orally at
160 and 200 mg/kg for 3 weeks significantly decreased
serum levels of ferritin to 8.6 ± 1.5 and 9.8 ± 1.5 ng/ml, re-
spectively, compared with mice that received vehicle alone
(18.3 ± 1.9 ng/ml; Table 2). While DFX administered at
160 and 200 mg/kg inhibited tumor growth and decreased
the serum levels of ferritin, the mice did not show body
weight loss or altered serum biochemistry, with the excep-
tion of the serum levels of ferritin (Fig. 5d and Table 2).
On the other hand, DFX administered at 120 mg/kg did
not significantly inhibit tumor growth, compared with
mice administered vehicle alone. Additionally, it is import-
ant to note that DFX administered at 120 mg/kg also failed
to reduce the serum levels of ferritin in mice. These obser-
vations are consistent with immunohistochemical studies
on tumor xenografts that performed semi-quantitative ana-
lyses of tumor sections. While tumors treated with 160
and 200 mg/kg oral DFX significantly reduced ferritin-H
protein levels compared with tumors treated with the
vehicle alone, tumors treated with 120 mg/kg oral DFX did
not significantly decrease the ferritin-H protein levels com-
pared with tumors treated with the vehicle alone (Fig. 6a
and b). These data indicated that tumor growth could be
suppressed when tumors were treated with a sufficient
dose of DFX, which functions as an iron chelator.
Table 1 IC50 values of DFX in three pancreatic cancer cell lines
after a 72-h incubation
BxPC-3 HPAF-II Panc 10.05
IC50 (μM) 7.3 ± 1.0 5.6 ± 1.0 6.1 ± 0.2
Fig. 2 DFX arrested the cell cycle at the S phase in pancreatic cancer cell lines. a BxPC-3, HPAF-II, and Panc 10.05 cells were incubated with the
vehicle control (PBS) or DFX at concentrations of 10, 50, or 100 μM for 72 h. The cell cycle phase of the treated cells was examined by flow
cytometry. The percentages of S phase cells are highlighted in pink. b The percentages of S phase cells in each concentration of DFX are shown.
When the cells were treated with 10 μM DFX, the number of cells in S phase increased in all three cell lines (n = 1)
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DFX downregulated genes in the pancreatic
adenocarcinoma signaling pathway
To investigate the genetic effect of DFX in pancreatic
cancer, we examined gene expression alternations in the
removed tumors exposed to DFX. From the results of
the cancer xenograft experiments, we found that the
tumors treated with 200 mg/kg oral DFX were suitable
for examining gene expression alterations. Thus, three
tumors were randomly chosen from the tumors treated
with 200 mg/kg oral DFX, and another three tumors
were randomly chosen from the control tumors. After
the whole genome microarray analysis, a total of 2412
genes were recognized as differentially expressed with a
significance cutoff of p <0.05. These genes were imported
into the IPA, and pathway analyses were performed. The
top canonical pathways are shown in Fig. 7a. Pancreatic
adenocarcinoma signaling was identified as one of the top
canonical pathways. This observation indicated that DFX
strongly affected xenografted pancreatic cancer genetically.
A heatmap of differently expressed genes included in pan-
creatic adenocarcinoma signaling is shown in Fig. 7c. Genes
highlighted in red indicate upregulation versus the control
tumors, while green indicates downregulation in the treated
tumors. According to the heatmap, most genes in the pan-
creatic adenocarcinoma signaling pathway were downregu-
lated by DFX. Specifically, transforming growth factor-ß1
(TGF- ß1) was strongly inhibited. The top upstream regula-
tors are shown in Fig. 7b; TGF- ß1 was also a top upstream
regulator. These data demonstrated that the antiprolifera-
tive activities of DFX were sustained genetically.
Fig. 3 DFX induced apoptosis in pancreatic cancer cell lines. a BxPC-3, HPAF-II, and Panc 10.05 cells were incubated with the vehicle control
(PBS) or DFX at 10, 50, or 100 μM for 72 h. DFX-treated BxPC-3, HPAF-II, and Panc 10.05 cells were stained with Annexin V/PI and examined by
flow cytometry. b The percentages of live, apoptotic, and necrotic cells are presented as the mean ± SD (n = 3). *p <0.05, **p <0.01 vs. control
Fig. 4 DFX increased caspase 3/7 activity in pancreatic cancer cell lines. BxPC-3, HPAF-II, and Panc 10.05 cells were incubated with the vehicle
control (PBS) or DFX at concentrations of 10, 50, or 100 μM for 48 h. Immediately after the incubation, caspase 3/7 activity was measured using a
luminescence assay and corrected for cell viability determined using the MTS assay. The corrected caspase 3/7 activities of BxPC-3, HPAF-II, and
Panc 10.05 cells incubated with DFX increased in a dose-dependent manner. The data are presented as the mean ± SD (n = 3). *p <0.05, **p <0.01
vs. control
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Discussion
The antiproliferative activity of iron chelators was first
demonstrated on leukemia in cell cultures and clinical
trials [24, 25]. Then, the antiproliferative activity of iron
chelators was demonstrated in solid tumors, including
pancreatic cancer tumors, and in cell culture in recent
studies [15, 26, 27]. DFO was the first commercially
available iron chelator to be used for the treatment of
iron-overload disease [28]. DFO has also been used for
studies researching the antiproliferative activity of iron
chelators in cell cultures and clinical trials [13–15, 25–27].
Although DFO exhibits antiproliferative activity, this
chelator has serious limitations because it is not utilized
by the body if administered orally and has a short serum
half-life. DFO needs to be given parenterally (either sub-
cutaneously or intravenous infusion) for long periods, typ-
ically 8–12 h per day, which has led to poor patient
compliance. On the other hand, DFX, a recently identified
iron chelator, can be administered orally once daily be-
cause it is orally active and has a long half-life of 7–18 h.
DFX is currently used for the treatment of iron-overload
disease and is considered an alternative to DFO [16]. The
antiproliferative activity of DFX has been investigated in
various cancers [22, 23, 29, 30]. However, there have
Fig. 5 Orally administered DFX markedly inhibited the growth of pancreatic cancer xenografts in nude mice. a DFX (160 and 200 mg/kg orally,
given by gavage every second day, for a total of three treatments per week for 21 days) significantly inhibited the growth of human pancreatic
cancer BxPC-3 xenografts in vivo. b The removed tumors were measured and processed for immunohistochemistry and genetic analyses. c The
removed tumors from mice treated with 160 and 200 mg/kg oral DFX weighed significantly less than the control tumors. d The average weight
of mice in each treatment group during the course of treatment
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previously been no studies of the effects of DFX in pancre-
atic cancer; this study is the first to elucidate the antipro-
liferative activity of DFX against pancreatic cancer cells.
We examined the in vitro antiproliferative activity of
DFX using an MTS assay in three pancreatic cancer cell
lines: BxPC-3, HPAF-II, and Panc 10.05. We observed a
dose-dependent antiproliferative activity of DFX in pan-
creatic cancer cell lines, consistent with the results of
previous studies in esophageal cancer cell lines [22] or
lung cancer cell lines [23]. Although a number of studies
have attempted to elucidate the anti-cancer mechanisms
of iron chelators, their mechanisms are not well known
[12]. Especially in pancreatic cancer, there have been few
studies investigating the effect of iron chelators as anti-
cancer agents [15]. To investigate the mechanisms of the
antiproliferative activity of DFX, we examined the effects
of DFX on the cell cycle and apoptosis in pancreatic
cancer cell lines. We observed that 10 μM DFX inhibited
pancreatic cancer cell proliferation by arresting the cell
cycle in the S phase, and 50 and 100 μM DFX inhibited
pancreatic cancer cell proliferation by inducing apop-
tosis. These anti-cancer mechanisms of DFX are con-
sistent with those found in previous reports for most
iron chelators [15, 31, 32].
We next assessed the ability of DFX to inhibit pancre-
atic cancer growth in vivo using a murine xenograft
model. We administered DFX at doses of 120, 160, and
200 mg/kg every second day, totaling three treatments
per week for 3 weeks. The doses of 160 and 200 mg/kg
of DFX successfully inhibited tumor growth and de-
creased serum and tumor levels of ferritin. Initially, we
attempted to administer DFX at doses of 20–40 mg/kg
every second day, for three treatments per week for 3 weeks
because a 20 mg/kg per day regimen is considered suitable
Table 2 Serum indices from nude mice bearing a BxPC-3 xenograft that were treated orally by gavage with either the vehicle
control or DFX (120, 160, or 200 mg/kg) every second day (three treatments per week) for 21 days
Units Treatment groups
Vehicle control Deferasirox
120 mg/kg 160 mg/kg 200 mg/kg
Ferritin ng/ml 18.3 ± 1.9 20.6 ± 2.9 8.6 ± 1.4* 9.8 ± 1.5*
Total protein g/dl 5.0 ± 0.3 5.4 ± 0.3 5.3 ± 0.4 5.3 ± 0.3
Albumin g/dl 3.2 ± 0.2 3.3 ± 0.1 3.4 ± 0.1 3.4 ± 0.1
Aspartate aminotransferase U/l 89.2 ± 15.8 106.2 ± 32.6 155.2 ± 97.9 146 ± 58.9
Alanine transaminase U/l 23.6 ± 1.9 29.2 ± 8.2 28.4 ± 9.6 28.8 ± 7.2
Lactate dehydrogenase U/l 243.6 ± 37.9 242.6 ± 18.2 243.8 ± 23.1 243.6 ± 21.7
Blood urea nitrogen mg/dl 560.6 ± 112.7 578.2 ± 65.5 669 ± 43.9 689.8 ± 101.9
Creatinine mg/dl 17.6 ± 1.2 14.2 ± 2.1 14.4 ± 0.6 15.8 ± 1.3
*p <0.05 vs. control
Fig. 6 Orally administered DFX reduced ferritin-H protein levels of removed tumors in immunohistochemical analyses. a Immunohistochemistry
was performed on the removed tumors with antibody specific to ferritin-H. b The slides were scored for the percentage of positive cells (0 = 0–5,
1 = 6–25, 2 = 26–50, 3 = 51–75 and 4 = 76–100 %) and intensity (0 = negative, 1 = weak, 2 =moderate, 3 = strong). The immunoreactivity score was
calculated as the percentage of positive cells multiplied by the score for the staining intensity. The immunoreactivity scores of removed tumors
treated orally with 160 and 200 mg/kg of DFX were significantly lower than that of control tumors. The data are presented as the mean ± SD
(n = 5 mice per group). For statistical analysis, each treatment was compared with the control. *p <0.05, **p <0.01 vs. control
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in patients with iron overload [33]. However, in nude mice,
20–40 mg/kg DFX did not inhibit tumor growth or reduce
serum levels of ferritin (data not shown). In fact, even a
dose of 120 mg/kg of DFX failed to significantly suppress
either tumor growth or serum and tumor ferritin levels.
The 3-week experiment may have been too short to assess
the effects of a normal dose of DFX in this xenograft
model. However, it is important to note that decreased
serum and tumor levels of ferritin were observed in the
mice that received 160 or 200 mg/kg doses of DFX admin-
istration, and the xenografted tumors were markedly sup-
pressed. Furthermore, no serious effects on body weight
and biological indices were observed. A previous in vivo
study using DFX also demonstrated the importance of iron
depletion in the xenografted tumor for cancer therapy [22].
According to our study, we believe that DFX demonstrates
antiproliferative activity by decreasing serum levels of fer-
ritin, which is reflected as iron depletion in the tumor.
To assess the genetic effects of DFX for pancreatic
cancer, we conducted microarray analysis using in vivo
samples. Most genes included in pancreatic adenocarcin-
oma signaling, especially TBF- ß1, were downregulated
by DFX administration. A previous study revealed that
TGF- ß overexpression is associated with early recur-
rence following resection and decreased survival in
patients with pancreatic cancer [34]. TGF- ß1 also plays
pivotal roles in driving epithelial-mesenchymal transition
(EMT) in the pathogenesis of pancreatic cancer [35, 36].
In fact, the TGF- ß signaling inhibitor displays antiprolif-
erative activity for pancreatic cancer [37]. A recent re-
view article also demonstrated that iron chelators can
target several pathways, including the TBF- ß pathway,
to subsequently inhibit cellular proliferation, EMT and
metastasis [38]. This evidence, combined with the results
of our microarray analysis, indicates that DFX works as
anticancer agent by suppressing TGF- ß signaling.
Conclusions
We first elucidated that DFX has potential as a thera-
peutic agent for pancreatic cancer. We demonstrated
that DFX inhibits pancreatic cancer cell growth by ar-
resting the cell cycle and inducing apoptosis. Further-
more, DFX inhibited pancreatic cancer growth in vivo in
a murine xenograft model. Genetically, TGF- ß1 plays a
key role in the effect of DFX against pancreatic cancer.
Because DFX is a commercially available oral iron chela-
tor, its clinical application can be considerable. While
further extensive studies are required, the DFX treat-
ment strategy can be considered a novel effective and
safe pancreatic cancer therapy in the near future.
Fig. 7 DFX downregulated the genes in pancreatic adenocarcinoma signaling. A total of six tumors, three tumors from mice treated with
200 mg/kg oral DFX, and three tumors from the controls, were chosen to examine gene expression alternation. A total of 2412 genes differentially
expressed with a significance cutoff of p <0.05 were imported into the IPA. a Top canonical pathways by DFX treatment in the removed tumors.
Pancreatic adenocarcinoma signaling was observed. b Top upstream regulators by DFX treatment in the removed tumors; TGF- ß1 was strongly
inhibited. c A heatmap of differently expressed genes in the Pancreatic Adenocarcinoma Signaling pathway. Most of the genes were downregulated
after DFX treatment
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